Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma

BACKGROUND: Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of patients not being cured. BCR-associated kinases (SYK, BTK...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: He, Yizi, Li, Jiao, Ding, Ning, Wang, Xiaogan, Deng, Lijuan, Xie, Yan, Ying, Zhitao, Liu, Weiping, Ping, Lingyan, Zhang, Chen, Song, Yuqin, Zhu, Jun
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6379963/
https://ncbi.nlm.nih.gov/pubmed/30777096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1076-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars